Rein Therapeutics (RNTX) Change in Account Payables (2016 - 2026)
Rein Therapeutics (RNTX) posted quarterly Change in Account Payables of $2.3 million for Q1 2026, up 861.34% year-over-year from $238000.0 in Q1 2025, and up 1656.46% quarter-over-quarter from -$147000.0 in Q4 2025.
Rein Therapeutics (RNTX) Change in Account Payables (2016 - 2026) Analysis & Trends
Rein Therapeutics (RNTX) has reported Change in Account Payables for 11 consecutive years, with $2.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Account Payables rose 861.34% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $5.1 million (up 607.94% YoY), while the FY2025 annual figure was $3.1 million, up 1198.57% from the prior year.
- Change in Account Payables grew to $2.3 million in Q1 2026 per RNTX's latest filing, from -$147000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $4.9 million in Q2 2025 and bottomed at -$3.7 million in Q4 2023.
- Historically, Change in Account Payables has averaged $35411.8 across 5 years, with a median of -$147000.0 in 2025.
- Annual changes were most pronounced in 2022 — Change in Account Payables slumped 4289.47% — and 2026, when it jumped 861.34%.
- Rein Therapeutics' Change in Account Payables stood at $775000.0 in 2022, then tumbled by 583.35% to -$3.7 million in 2023, then surged by 95.52% to -$168000.0 in 2024, then increased by 12.5% to -$147000.0 in 2025, then jumped by 1656.46% to $2.3 million in 2026.
- Business Quant data shows RNTX's Change in Account Payables at $2.3 million in Q1 2026, -$147000.0 in Q4 2025, and -$1.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Rein Therapeutics | 55.49 Mn | 55.49 Mn | - | -1.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.89 Mn |
| Jun 30, 2026 | -1.89 Mn |
| Mar 31, 2026 | 2.29 Mn |
| Mar 31, 2026 | 2.29 Mn |
| Dec 31, 2025 | -147,000.00 |
| Dec 31, 2025 | -147,000.00 |
| Sep 30, 2025 | -1.91 Mn |
| Sep 30, 2025 | -1.91 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Jun 30, 2025 | 4.88 Mn |
| Mar 31, 2025 | 238,000.00 |
| Mar 31, 2025 | 238,000.00 |
| Dec 31, 2024 | -168,000.00 |
| Dec 31, 2024 | -168,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Sep 30, 2024 | 297,000.00 |
| Jun 30, 2024 | -1.37 Mn |
| Jun 30, 2024 | -1.37 Mn |
| Mar 31, 2024 | 966,000.00 |
| Mar 31, 2024 | 966,000.00 |